This website is intended for healthcare professionals only and contains promotional content.
United Kingdom - English
United Kingdom | English
These country specific websites are specifically intended for healthcare professionals in listed countries only.
NOTICE: Kyowa Kirin International has agreed a joint venture with Grünenthal GmbH for the Established Medicines portfolio. The new company, KKI NewCo (known as Grünenthal Meds), is responsible for the content on this page. For more information please click here.
MOVENTIG is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).1
Definition of laxative inadequate responder (LIR): In the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.1
Adverse Events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse Events should also be reported to Kyowa Kirin International UK NewCo Ltd, known as Grünenthal Meds on +44 (0)1896 664000, email PVUK@grunenthalmeds.com
Click here for Prescribing Information.
Explore our interactive module to learn about OIC, how it can affect your patients, why laxatives are often not effective for OIC,2 and how MOVENTIG can help target OIC at its source.1
MOVENTIG (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). For advice on the responsible use of opioids to treat pain, please click here
1. MOVENTIG Summary of Product Characteristics.
2. Camilleri M, et al. Neurogastroenterol Motil. 2014;26(10):1386–139.
Deutschland
- Deutsch
España
- Español
Italia
- Italiano